NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Medical Marketing & Media13h
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Chosunbiz22h
Lotte Biologics partners with Asimov for CDMO collaboration in US
Lotte Biologics announced on the 13th that it has signed a memorandum of understanding (MOU) for collaboration in the ...
Trump’s Chips War Has Left Intel’s New CEO With a Near-Impossible Task. Here’s Why and 5 Other Things to Know Today.
Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...
Zacks Investment Research on MSN14h
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral and ...